istock-635475308-1-

CIPhotos / iStockphoto.com

15 February 2018Americas

BMS pays $1.85bn for immuno-oncology programme

Bristol-Myers Squibb (BMS) has agreed to pay $1.85 billion for an immuno-oncology programme.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Roche to make $1.9bn acquisition

19 February 2018 Switzerland-based Roche has revealed plans to acquire a healthcare technology company for $1.9 billion.

Bristol-Myers Squibb to acquire Celgene in $74bn deal

3 January 2019 American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.

BMS partners with drug accelerator to launch biotech

5 February 2020 Bristol-Myers Squibb and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.

More on this story

Roche to make $1.9bn acquisition

19 February 2018 Switzerland-based Roche has revealed plans to acquire a healthcare technology company for $1.9 billion.

Bristol-Myers Squibb to acquire Celgene in $74bn deal

3 January 2019 American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.

BMS partners with drug accelerator to launch biotech

5 February 2020 Bristol-Myers Squibb and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.

More on this story

Roche to make $1.9bn acquisition

19 February 2018 Switzerland-based Roche has revealed plans to acquire a healthcare technology company for $1.9 billion.

Bristol-Myers Squibb to acquire Celgene in $74bn deal

3 January 2019 American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.

BMS partners with drug accelerator to launch biotech

5 February 2020 Bristol-Myers Squibb and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Attorney v examiner: Navigating patenting's AI tools ‘arms race’

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool